title: [Clinical and pharmacokinetics studies of ceftriaxone upon 2g once daily administration in respiratory tract infections].
abstract: Clinical studies on ceftriaxone (CTRX) were conducted with 2 g once daily administration to respiratory tract infections. In addition, CTRX concentrations in serum, sputum and urine were determined. The results obtained are summarized as follows: 1. Clinical responses to CTRX in a total of 29 cases with respiratory tract infections were excellent in 7 cases, good in 13, fair in 8 and poor in 1 with a response rate of 69.0%. 2. CTRX concentrations in serum, sputum and urine (total and free body) were determined in 3 cases after intravenous drip infusion of 2g CTRX. Peak levels in sputum were 2.6 to 7.8 micrograms/ml, and CTRX maintained high sputum levels for 12 to 24 hours after administration.
authors.affiliation: Second Department of Internal Medicine, Hiroshima University.
authors.forename: S
authors.initials: S
authors.lastname: Ishioka
authors.forename: H
authors.initials: H
authors.lastname: Yamakido
authors.forename: K
authors.initials: K
authors.lastname: Inyaku
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Yamakido
authors.forename: T
authors.initials: T
authors.lastname: Akagawa
authors.forename: M
authors.initials: M
authors.lastname: Kuwabara
authors.forename: Y
authors.initials: Y
authors.lastname: Kodomari
authors.forename: M
authors.initials: M
authors.lastname: Kawamoto
authors.forename: H
authors.initials: H
authors.lastname: Arita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002443:Ceftriaxone / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000378:metabolism; D013183:Sputum / Q000378:metabolism
chemical_list: D002443:Ceftriaxone